UNSPSC 51343824: Emtricitabine/Tenofovir Alafenamide/Bictegravir

Bictegravir/emtricitabine/tenofovir alafenamide, is a fixed-dose combination antiretroviral medication for the treatment of HIV/AIDS.

UNSPSC 51343824 Emtricitabine/Tenofovir Alafenamide/Bictegravir is a Commodity code that shows no meaningful recent state and local procurement activity aligned with the pharmaceutical product specified in the code. The source records reflect a mismatch between the code's nominal scope—a specific antiretroviral combination therapy—and the actual work being solicited under it. Recent opportunities tagged to this code span emergency medical services mobile applications, long-term care pharmacy services, aquatic facility operations, pharmacy network qualification, naloxone distribution, general contractor prequalification, group purchasing organization membership, basic and advanced life support pharmaceuticals and supplies, community mental health prescription services, drug reference standards for forensic analysis, and county networking events. None of these solicitations target procurement of emtricitabine/tenofovir alafenamide/bictegravir specifically or antiretroviral therapy more broadly.

No state or local jurisdiction has posted a direct solicitation for emtricitabine/tenofovir alafenamide/bictegravir during the recent activity window. The code's assignment to diverse, unrelated state and local contract notices suggests either upstream classification error or use of the code as a placeholder in procurement systems without active demand. Business development professionals should treat this code as currently inactive for state and local government contracting purposes and verify category assignment with issuing jurisdictions before investing pursuit resources.